Connect
MJA
MJA

Updates and advances in the treatment of Parkinson disease

Michael W Hayes, Victor SC Fung, Thomas E Kimber and John D O'Sullivan
Med J Aust 2019; 211 (6): . || doi: 10.5694/mja2.50224
Published online: 17 June 2019

Summary

  • Parkinson disease (PD) is a complex neurodegenerative disorder that can present heterogeneously with a combination of motor and non‐motor symptoms.
  • α‐synuclein, a neuronal protein, can undergo aberrant conformational change resulting in the intra‐neuronal accumulation of toxic oligomers that form Lewy bodies, the pathological hallmark of PD.
  • There is evidence that pathological α‐synuclein exhibits prion‐like behaviour in its mode of transmission through the nervous system.
  • The choice of initial dopaminergic treatments should be individually tailored but long term outcomes appear to be equivalent.
  • There is level A evidence supporting the benefit of three different device‐assisted therapies in treating troublesome motor fluctuations and dyskinesias.
  • Stem cell transplantation as currently being trialled is predominantly a symptomatic therapy targeting only limited regions of the brain affected by PD, and will need to be proven to be not only as effective but as safe as currently available device‐assisted therapies.
  • New modes of treatment including active immunisation against oligomeric α‐synuclein and drugs that alter cellular metabolism show some promise.
  • The inability to effectively treat a range of non‐motor, non‐dopaminergic symptoms remains a major therapeutic challenge.

  • 1 Concord Repatriation General Hospital, Sydney, NSW
  • 2 Sydney Medical School, University of Sydney, Sydney, NSW
  • 3 Westmead Hospital, Sydney, NSW
  • 4 Royal Adelaide Hospital, Adelaide, SA
  • 5 University of Adelaide, Adelaide, SA
  • 6 Royal Brisbane and Women's Hospital, Brisbane, QLD
  • 7 University of Queensland, Brisbane, QLD



Competing interests:

No relevant disclosures.

  • 1. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015; 30: 1591–1599.
  • 2. Rizzo G, Copetti M, Arcuti S, et al. Accuracy of the clinical diagnosis of Parkinson disease: a systematic review and meta‐analysis. Neurology 2016; 86: 566–576.
  • 3. Olanow CW, Brundin P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion‐like disorder? Mov Disord 2013; 28: 31–40.
  • 4. Luk KC, Kehm V, Carroll J, et al. Pathological α‐synuclein transmission initiates Parkinson‐like neurodegeneration in non‐transgenic mice. Science 2012; 338: 949–953.
  • 5. Schenk CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older males initially diagnosed with idiopathic REM sleep behaviour disorder (RBD): a 16 year update on a previously reported series. Sleep Med 2013; 14: 744–748.
  • 6. Postuma RB, Gagnon JF, Bertrand JA, et al. Parkinson risk in idiopathic REM sleep behaviour disorder: preparing for neuroprotective trials. Neurology 2015; 84: 1104–1113.
  • 7. Knudsen K, Fedorova TD, Hansen AK, et al. In vivo staging of pathology in REM sleep behaviour disorder: a multi‐modal imaging case‐control study. Lancet Neurol 2018; 17: 618–628.
  • 8. Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002; 17: 60–67.
  • 9. Bloem BR, Stocchi F. Move for change part I: a European survey evaluating the impact of the EPDA Charter for People with Parkinson's disease. Eur J Neurol 2012; 19: 402–10.
  • 10. Chaudhuri KR, Fung VSC. Fast facts: Parkinson's disease. Oxford: Health Press Limited, 2016.
  • 11. Antonini A, Barone P, Marconi R, et al. The progression of non‐motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. J Neurol 2012; 259: 2621–2631.
  • 12. Grosset D, Taurah L, Burn DJ, et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 2007; 78: 465–469.
  • 13. Titova N, Levin O, Katunina E, Ray Chaudhuri K. ‘Levodopa phobia’: a review of a not uncommon and consequential phenomenon. NPJ Parkinsons Dis 2018; 4: 31.
  • 14. Olanow CW, Rascol O, Hauser R, et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268–1278.
  • 15. Schapira AH, McDermott MP, Barone P, et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed‐start trial. Lancet Neurol 2013; 12: 747–755.
  • 16. Verschuur CV, Suwijn SR, Post B, et al. Protocol of a randomised delayed‐start double‐blind placebo‐controlled multi‐centre trial for Levodopa in EArly Parkinson's disease: the LEAP study. BMC Neurol 2015; 15: 236.
  • 17. Gray R, Ives N, Rick C, et al. Long‐term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open‐label, pragmatic randomised trial. Lancet 2014; 384: 1196–1205.
  • 18. Kim SD, Allen NE, Canning CG, Fung VSC. Parkinson disease. Handb Clin Neurol 2018; 159: 173–193.
  • 19. Schenkman M, Moore CG, Kohrt WM, et al. Effect of high‐intensity treadmill exercise on motor symptoms in patients with de novo parkinson disease: a phase 2 randomized clinical trial. JAMA Neurol 2018; 75: 219–226.
  • 20. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community‐based study. Brain 2000; 124: 1765–1776.
  • 21. Marrinan S, Emmanuel AV, Burn DJ. Delayed gastric emptying in Parkinson's disease. Mov Disord 2014; 29: 23–32.
  • 22. Nutt JG, Woodward WR, Hammerstad JP, et al. The “on‐off” phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984; 310: 483–488.
  • 23. Pierantozzi M, Pietroiusti A, Brusa L, et al. Helicobacter pylori eradication and l‐dopa absorption in patients with PD and motor fluctuations. Neurology 2006; 66: 1824–1829.
  • 24. Rahne KE, Tagesson C, Nyholm D. Motor fluctuations and Helicobacter pylori in Parkinson's disease. J Neurol 2013; 260: 2974–2980.
  • 25. Marrinan SL, Otiker T, Vasisit LS, et al. A randomised, double‐blind, placebo‐controlled trial of camicinal in Parkinson's disease. Mov Disord 2018; 33: 329–332.
  • 26. Obeso JA, Rodriguez‐Oroz M, Marin C, et al. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 2004; 62 Suppl 1: S17–S30.
  • 27. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting Effect in Adjunct Therapy with Rasagiline given once daily): a randomised, double‐blind, parallel‐group trial. Lancet 2005; 365: 947–954.
  • 28. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double‐blind, double‐dummy, randomised controlled trial. Lancet Neurol 2007; 6: 513–520.
  • 29. Schrag A. Entacapone in the treatment of Parkinson's disease. Lancet Neurol 2005; 4: 366–70.
  • 30. Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end‐of‐dose motor fluctuations: a randomised, double‐blind, controlled trial. Lancet Neurol 2016; 15: 154–165.
  • 31. Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double‐blind, randomized, placebo‐controlled study (RECOVER). Mov Disord 2011; 26: 90–99.
  • 32. Nyholm D, Stepien V. Levodopa fractionation in Parkinson's disease. J Parkinsons Dis 2014; 4: 89–96.
  • 33. Caccia C, Maj R, Calabresi M, et al. Safinamide. From molecular targets to a new anti‐Parkinsonian drug. Neurology 2006; 67 Suppl 2: S18–S23.
  • 34. Schapira AHV, Fox SH, Hauser RA, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations. A randomized clinical trial. JAMA Neurol 2017; 74: 216–224.
  • 35. Murata M, Hasegawa K, Kanazawa I, et al. Zonisamide improves wearing‐off in Parkinson's disease: a randomized, double‐blind study. Mov Disord 2015; 30: 1343–1350.
  • 36. Dewey RB, Hutton TJ, Le Witt PA, Factor SA. A randomized, double‐blind, placebo‐controlled trial of subcutaneously injected apomorphine for Parkinsonian off‐state events. Arch Neurol 2001; 58: 1385–1392.
  • 37. Oertel W, Eggert K, Pahwa R, et al. Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3). Mov Disord 2017; 32: 1701–1709.
  • 38. Williams DR, Evans AH, Fung VSC, et al. Practical approaches to commencing device‐assisted therapies for Parkinson disease in Australia. Intern Med J 2017; 47: 1107–1113.
  • 39. Deuschl G, Schade‐Brittinger C, Krack P, et al. A randomized trial of deep brain stimulation for Parkinson's disease. N Engl J Med 2006; 355: 896–908.
  • 40. Odekerken VJJ, van Laar T, Staal MJ, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurol 2013; 12: 37–44.
  • 41. Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with parkinson's disease with persistent motor fluctuations (TOLEDO): a multicenter, double‐blind, randomised, placebo‐controlled trial. Lancet Neurol 2018; 17: 749–759.
  • 42. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa‐carbidopa intestinel gel for patients with advanced Parkinson's disease: a randomised, controlled, double‐blind, double‐dummy study. Lancet Neurol 2014; 13: 141–149.
  • 43. Kimber TE, Fang J, Huddy LJ, Thompson PD. Long‐term adherence to apomorphine infusion in patients with Parkinson's disease: a 10 year observational study. Intern Med J 2017; 47: 570–573.
  • 44. Schuepbach WMM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013; 368: 610–622.
  • 45. Odin P, Ray Chaudhuri K, Slevin JT, et al. Collective clinician perspectives on non‐oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: consensus from an international survey and discussion program. Parkinsonism Rel Disord 2015; 21: 1133–1144.
  • 46. Titova N, Chaudhuri KR. Non‐motor Parkinson disease: new concepts and personalised management. Med J Aust 2018; 208: 404–409. https://www.mja.com.au/journal/2018/208/9/non-motor-parkinson-disease-new-concepts-and-personalised-management .
  • 47. Chaudhuri KR, Martinez‐Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006; 21: 916–923.
  • 48. Pierantozzi M, Placidi F, Liguori C, et al. Rotigotine may improve sleep architecture in Parkinson's disease: a double‐blind, randomized, placebo‐controlled polysomnographic study. Sleep Med 2016; 21: 140–144.
  • 49. Lim TT, Kluger BM, Rodriguez RL, et al. Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease. Mov Disord 2015; 30: 1825–1830.
  • 50. Hauser RA, Isaacson S, Lisk JP, et al. Droxidopa for the short‐term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). Mov Disord 2015; 30: 646–654.
  • 51. Espay AJ, LeWitt PA, Hauser RA, et al. Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. Lancet Neurol 2016; 15: 954–966.
  • 52. Zesiewicz TA, Evatt M, Vaughan CP, et al. Randomised, controlled pilot of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism Rel Dis 2015; 21: 514–520.
  • 53. Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review. Mov Disord 2019; 34: 180–198.
  • 54. Forsaa EB, Larsen JP, Wentzel‐Larsen T, et al. A 12‐year population‐based study of psychosis in Parkinson disease. Arch Neurol 2010; 67: 996–1001.
  • 55. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo‐controlled phase 3 trial. Lancet 2014; 383: 533–540.
  • 56. Friedman JH. Quetiapine for Parkinson's disease psychosis: evidence‐based medicine versus expert belief: A case study. Mov Disord 2018; 33: 1186–1187.
  • 57. Weintraub D, David AS, Evans AH, et al. Clinical spectrum of impulse control disorders in Parkinson's disease. Mov Disord 2015; 30: 121–127.
  • 58. Okai D, Askey‐Jones S, Samuel M, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology 2013; 80: 792–799.
  • 59. Sabbagh MN, Adler CH, Lahti TJ, et al. Parkinson's disease with dementia: comparing patients with and without Alzheimer's pathology. Alzheimer Dis Assoc Disord 2009; 23: 295–297.
  • 60. Freitas ME, Ruiz‐Lopez M, Fox SH. Novel levodopa formulations for Parkinson's disease. CNS Drugs 2016; 30: 1079–1095.
  • 61. Hauser RA, Hsu A, Kell S, et al. Extended‐release carbidopa‐levodopa (IPX066) compared with immediate‐release carbidopa‐levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double‐blind trial. Lancet Neurol 2013; 12: 346–356.
  • 62. Stocchi F, Vacca L, Stirpe P, Torti M. Pharmacokinetic drug evaluation of CVT‐301 for the treatment of Parkinson's disease. Expert Opin Drug Metab Toxicol 2018; 14: 1189–1195.
  • 63. Barker RA, Studor L, Catteneo E, Takahashi J. G‐Force PD: a global initiative in coordinating a stem cell‐based dopamine treatment for Parkinson's disease. NPJ Parkinson Dis 2015; 1: 15017.
  • 64. Whone A, Luz M, Boca M, et al. Randomized trial of intermittent intraputamenal glial cell line‐derived neurotrophic factor in Parkinson's disease. Brain 2019; 142: 512–525.
  • 65. Jankovic J, Goodman I, Safirstein B, et al. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti‐α‐synuclein monoclonal antibody in patients with Parkinson disease. JAMA Neurol 2018; 75: 1206–1214.
  • 66. Cereda A, Barichella M, Pedrolli C, et al. Diabetes and risk of Parkinson's disease: a systematic review and meta‐analysis. Diabetes Care 2011; 34: 2614–2623.
  • 67. Foltynie T, Athuda D. Gluacagon‐like peptides (GLP‐1) perspectives in synucleinopathies treatment. Mov Disord Clin Pract 2018; 5: 255–258.
  • 68. Siebert M, Sidransky E, Westbroek W. Glucocebrosidase is shaking up the synucleinopathies. Brain 2014; 137(Pt 5): 1304–1322.
  • 69. McNeill A, Magalheas J, Shen C, et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation‐linked Parkinson disease cells. Brain 2014; 137(Pt 5): 1481–1495.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.